Herpes Simplex, Genital & Neonatal

1. DISEASE REPORTING

A. Purposes of Reporting and Surveillance

To assess trends in epidemic patterns, understand the impact of the burden of disease on populations and the health care infrastructure, and to better target population-level disease prevention efforts.

B. Legal Reporting Requirements

1. Health care providers: initial genital and all neonatal infections are notifiable to local health jurisdiction within three (3) work days. Cases should be reported using the Sexually Transmitted Disease (STD) Morbidity Report Form. See: http://www.doh.wa.lcl/YouandYourFamily/IllnessandDisease/SexuallyTransmittedDisease/CaseReports.aspx

2. Hospitals: no requirements for reporting

3. Laboratories: no requirements for reporting

4. Local health jurisdictions: notify the Washington State Department of Health (DOH), STD Services Section within seven (7) days of case investigation completion; summary information required within 21 days for all reported cases. Enter case report information into the Public Health Issue Management System – Sexually Transmitted Disease (PHIMS-STD).

C. Local Health Jurisdiction Investigation Responsibilities

1. Herpes simplex cases should be reported to DOH using the PHIMS-STD system to enter investigation information including provider case report, laboratory, interview, and partner management data.

2. THE DISEASE AND ITS EPIDEMIOLOGY

A. Etiologic Agent

Herpes simplex virus (HSV) is in the virus family herpes viridae, subfamily Alphaherpesvirinae. HSV 1 and 2 can be differentiated immunologically and differ with respect to their growth patterns in cell culture, embryonated eggs and experimental animals.

B. Description of Illness

Herpes simplex is commonly asymptomatic. Infection is characterized by a localized primary lesion, latency and tendency to localized recurrence. The primary lesions in women are on the cervix, and vulva. In men, lesions appear on the glans penis or prepuce, and in the anus and/or rectum of those engaging in anal sex. Lesions may be present in other genital or perineal sites as well as the mouth, in men and women depending on sexual practices.
The disease is severe for infants, can result in fetal malformation, severe mental retardation, brain damage or infant mortality. For pregnant women who are infected, spontaneous abortion or premature delivery could occur. The risk of neonatal infection is a primary reason for caesarian section delivery among women with genital herpes infections.

C. Herpes in Washington State

During recent years, DOH has received approximately 2,000 reports of initial genital HSV infection per year and less than 10 cases of neonatal herpes per year. To view the most recent morbidity information on reported herpes cases, see: http://www.doh.wa.lcl/YouandYourFamily/IllnessandDisease/SexuallyTransmittedDisease/MorbidityReports.aspx

D. Reservoir

Humans.

E. Modes of Transmission

Contact with HSV 1 virus in the saliva of carriers is probably the most important mode of spread. HSV type 2 is usually sexually transmitted. Both types 1 and 2 may be transmitted to various sites by oral-genital, oral-anal or anal-genital contact.

Transmission to newborns usually occurs via the infected birth canal, but less commonly occurs in utero or postpartum.

F. Incubation Period

Usually from 2 to 12 days.

G. Period of Communicability

HSV can be isolated for 2 weeks and up to 7 weeks after the appearance of primary lesions. Both primary and recurrent infection may be asymptomatic. HSV may be shed intermittently from mucosal sites for years and possibly lifelong.

H. Treatment

Treatment options include acyclovir, famciclovir and valacyclovir. See full CDC treatment guidelines at: http://www.cdc.gov/std/treatment/2010/STD-Treatment-2010-RR5912.pdf

3. CASE DEFINITIONS

A. Clinical Criteria for Diagnosis

A condition characterized by visible, painful genital or anal lesions. The clinical diagnosis of herpes is both insensitive and non-specific.

B. Laboratory Criteria for Diagnosis

Since the distinction between HSV serotypes influence prognosis and counseling, HSV should be confirmed by laboratory testing (virologic or type-specific serologic tests).

Virologic Tests:

1. Isolation of HSV in cell culture is a preferred virologic test in patients who present
with genital ulcers or other mucocutaneous lesions. However, the sensitivity declines rapidly as lesions begin to heal. Culture isolates should be typed to determine the HSV serotype causing the infection.

2. PCR (polymerase chain reaction) assays for HSV DNA are more sensitive and are increasingly used. In addition, PCR is the test of choice for HSV in spinal fluid to detect central nervous system disease.

3. Cytologic detection of cellular changes of HSV is insensitive and nonspecific. Tzanck preparation and Pap smears should not be considered reliable for HSV detection.

**Type-specific Serologic Tests:**

1. Both type specific and nonspecific antibodies to HSV develop during the first several weeks following infection and persist indefinitely. Accurate type-specific tests rely on glycoprotein G2 for HSV-2 and G1 for HSV-1 detection. Older, non-gG based tests remain on the market and should not be used.

2. False-negative results may occur, especially in the early stages of infection. False-positive results may occur, especially in patients with a low likelihood of HSV infection. Therefore, repeat or confirmatory testing may be indicated in some settings.

3. Routine screening for HSV-1 and –2 infections in the general population is not indicated. Type specific HSV testing might be useful in the following scenarios: 1) recurrent genital symptoms or atypical symptoms with negative HSV cultures, 2) a clinical diagnosis of genital herpes without laboratory confirmation, or 3) a partner with genital herpes.

**C. Case Definition**

Probable: a clinically compatible case (in which primary and secondary syphilis have been excluded by appropriate serologic tests and darkfield microscopy, when available) with either a diagnosis of genital herpes based on clinical presentation (without laboratory confirmation) or a history of one or more previous episodes of similar genital lesions.

Confirmed: a clinically compatible case that is laboratory confirmed.

Only a patient’s first disease episode (and neonatal infections) are notifiable in Washington State; recurrent episodes are not reportable.

**4. DIAGNOSIS AND LABORATORY SERVICES**

**A. Diagnosis**

As noted above, the clinical diagnosis of herpes is both insensitive and non-specific. The case report for Herpes Simplex is for initial genital infection. This diagnosis can be made by a clinician and cases should be reported with or without the presence of laboratory confirmation.

**B. Tests Available at PHL**
C. Criteria for Testing at PHL
   Not Applicable.

D. Specimen Transport
   Not Applicable.

5. ROUTINE CASE INVESTIGATION

A. Evaluate the Diagnosis
   There is no case investigation performed for HSV infections.

B. Identify Source of Infection
   Since there are no case investigations for adult genital infections, the source of infection is not identified.

C. Managing Potentially Exposed Persons
   Potentially exposed persons (sexual partners) should be informed of the possible exposure by the infected individual.

D. Environmental Evaluation
   None applicable.

6. CONTROLLING FURTHER SPREAD

A. Infection Control Recommendations
   1. Health care setting
      Standard Precautions are a set of protocols designed to reduce the risk of (or prevent) transmission of pathogens. Standard precautions synthesize the major features of Universal (Blood and Body Fluid) Precautions (designed to reduce the risk of transmission of bloodborne pathogens) and Body Substance Isolation (designed to reduce the risk of transmission of pathogens from moist body substances). Under standard precautions blood, all body fluids, and all body substances of patients are considered potentially infectious (CDC, 1997).

      For more information, see CDC Program Guidelines: http://www.cdc.gov/std/program/med&lab.pdf

      Neonatal Herpes Infection - Both HSV-1 and HSV-2 can cause potentially fatal infections in infants if the mother is shedding virus, either through active lesions or through the skin, at the time of delivery. It is important that women avoid contracting herpes during pregnancy because a first episode during pregnancy causes a greater risk of transmission to the newborn. If a woman has active genital herpes at delivery, a cesarean section is usually the preferred method of delivery.

   2. General
      Genital ulcer diseases can occur in both male and female genital areas that are protected by a condom, as well as in areas that are not covered. When used consistently and
correctly, condoms are effective in reducing, but not eliminating the risk of genital herpes.

B. Case Management
   See routine case investigation in Section 5 above.

C. Contact Management
   See routine case investigation in Section 5 above.

D. Management of Other Exposed Persons
   See routine case investigation in Section 5 above.

E. Environmental Measures
   None applicable.

7. MANAGING SPECIAL SITUATIONS
   Call the Department of Health STD Services for special situations. (360 236-3460)

8. ROUTINE PREVENTION
   A. Vaccine Recommendations
      No vaccine currently exists for herpes simplex.

   B. Prevention Recommendations
      Key individual STD prevention messages include:

      Abstinence
      Abstain from sex (do not have oral, anal, or vaginal sex) until you are in a relationship
      with only one person, are having sex with only each other, and each of you knows the
      other’s STD, including HIV, status.

      If you have, or plan to have, more than one sex partner:
      ▪ Use a latex condom and lubricant every time you have sex.
      ▪ Get tested for asymptomatic STDs including HIV.
      ▪ If you are a man who has had sex with other men, get tested at least once a year.
      ▪ If you are a woman who is planning to get pregnant or who is pregnant, get tested for
        syphilis and HIV as soon as possible, before you have your baby. Ask your health
        care provider about being tested for other STDs.
      ▪ Talk about STDs, including HIV, with each partner before you have sex.
      ▪ Learn as much as you can about each partner’s past behavior (sex and drug use).
      ▪ Ask your partners if they have recently been treated for an STD or have been tested
        for HIV; encourage those who have not been tested to do so.

      Key STD prevention strategies include:

      STD prevention counseling, testing, and referral services – Individuals at risk for STD
      should be offered counseling regarding methods to eliminate or reduce their risk and
testing so that they can be aware of their status and take steps to protect their own health and that of their partners.

**Partner Services (or Partner Notification) with strong linkages to prevention and treatment/care services** – Sexual partners of STD-infected persons have been exposed to an STD and are at-risk of being infected. Partner services locate these individuals based on information provided by the patient and provide counseling and education about the exposure as well as services to prevent infection or, if infected, linkages to care.

**Prevention for high-risk populations** – Prevention interventions for high-risk populations at high-risk for STDs, including HIV-infected persons, are critical to reducing the spread of STDs and HIV and ensure that those at highest risk of acquiring or transmitting these diseases are given the tools necessary to protect themselves and others from HIV infection. Prevention includes targeted health education and risk reduction, health communication programs, and public information programs for at-risk populations and the general public.

**School-based STD Prevention** – Schools have a critical role to play in promoting the health and safety of young people and helping them establish lifelong healthy behavior patterns. Washington State requires schools to teach medically accurate comprehensive sex education if such is provided by the school district.

---

**ACKNOWLEDGEMENTS**

We would like to acknowledge the Oregon Department of Human Services for developing the format and select content of this document.

For persons with disabilities, this document is available on request in other formats. To submit a request, please call 1-800-525-0127 (TDD/TTY 1-800-833-6388).